Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial
November 24, 2015 at 07:12 AM EST
Novogen Limited (NASDAQ: NVGN), announced today that it has engaged Novotech as the Contract Research Organisation (CRO) to conduct its ...
